/ print page

provides preclinical, pharmacological testing of potential novel compounds and approaches for therapy and diagnostics of cancer

	was founded by Dr. I. Fichtner and Dr. Ch. Nowak in 1997 as a spin-off from the Max-Delbrück-Center for Molecular Medicine [MDC] and has been constantly growing.
	has main in the testing of novel therapeutics for antitumour activity in vitro and in vivo. Technology is also available to study the engraftment and tumourigenicity of human cells in mice.
	has available modern laboratories licenced for animal experiments, gene technology and radioactive experiments.
	offers a broad panel of human tumours xenotransplanted in immunodeficient mice or murine tumours growing in syngeneic immunocompetent strains.
	offers a broad spectrum of services using state of the art technologies and develops tailor-made testing procedures considering special concepts or ideas of sponsors.
	has filed an extensive database compiling preclinical data of reference and experimental agents.
	has eatablished a databank with genomic and proteomic profiles of patient-derived malignomas
	works with excellently trained scientific and technical staff.